通过非活化PSMB8-ATRAP信号,Lentinan可以改善与高血压相关的血管损伤
Denghui Zhao1, Yuwei Cai1, Bingqi Chen1
1Department of Nutrition and Toxicology, School of Public Health, Hangzhou Normal University, Hangzhou, China.
International immunopharmacology
|August 27, 2025
概括
通过抑制免疫蛋白酶PSMB8,增加ATRAP和禁用炎症通路,Lentinan (LNT) 能够防止高血压引起的肠道屏障损伤. 这表明LNT是高血压相关肠道损伤的潜在治疗方法.
科学领域:
- 心血管研究
- 胃肠病学
- 免疫学
背景情况:
- 肠道屏障损伤是高血压的一个重要并发症.
- 血管素II (Ang II) 在高血压及其相关疾病中起着关键作用.
- 抗胰岛素II类型1受体相关蛋白 (ATRAP) 调节Ang II的作用,其调节涉及免疫蛋白酶子单元PSMB8.
研究的目的:
- 研究Lentinan (LNT) 在缓解Ang II引起的高血压和肠道屏障损伤方面的治疗潜力.
- 阐明LNT具有保护作用的基础分子机制.
主要方法:
- 使用Ang II输液建立了小鼠高血压模型.
- 在 Ang II 输注前和输注期间,小鼠接受了不同剂量的 LNT (来自 Lentinus edodes 的多糖) 治疗.
- 对血压,大动脉重塑,血管功能,氧化应激,肠道损伤和屏障完整性的评估.
- 研究了LNT对PSMB8免疫蛋白酶活性/表达,ATRAP水平和关键信号通路 (NF-κB,ERK1/2,TGF-β) 的影响.
主要成果:
- 根据LNT剂量减弱的Ang II诱导的高血压,血管损伤和氧化应激.
- LNT显著改善了肠道病变,炎症和屏障破坏.
- 在机理上,LNT抑制了PSMB8,导致ATRAP增加,并且禁用了NF-κB,ERK1/ 2和TGF-β信号.
- 通过敲击实验证明,LNT的保护作用依赖于ATRAP.
结论:
- 在改善高血压和相关肠道屏障损伤方面,Lentinan具有显著的治疗潜力.
- LNT的机制涉及免疫蛋白酶-ATRAP轴和下游炎症信号通路的调节.
- 对于治疗高血压相关的胃肠道并发症而言,LNT 是一个有前途的新疗法.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
911
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
911
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:25Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817